“The suit filed against Sanofi comes at the heels of Sanofi having received marketing approval for a Whole Cell Pertussis based Hexavalent vaccine by the Drugs Controller General (India),” Panacea Biotec mentioned in a regulatory submitting.
On May 11, 2021, when the suit was listed earlier than the Delhi High Court, after elaborate submissions from each events, Sanofi undertook that it couldn’t manufacture or market any product which infringes the amended claims of Panacea patent, it added.
Panacea mentioned Sanofi has been contesting the patent earlier than the Indian Patent Office since 2017, the place the dispute has spilled earlier than the Bombay and Delhi High Courts in 2018 and 2019, respectively.
The EasySix vaccine is available in a pre-filled syringe and is used to vaccinate against Diphtheria, Tetanus, Whooping Cough, Hepatitis B, Haemophilus influenza Type B and Inactivated Polio.
EasySix has been out there since 2017 and the corporate expects it to be part of authorities vaccination, immunisation programmes, each domestically and internationally, Panacea Biotec famous.
Panacea Biotec shares have been buying and selling 1.63 per cent down at Rs 374.30 apiece on the BSE.